Arovella Therapeutics (ALA) H2 2026 earnings summary

Executive summary

• Transitioned from preclinical to clinical-stage cell therapy, advancing lead product ALA-101 into Phase 1 trials after US FDA IND clearance and ethics approval in Australia.

• Expanded platform potential with ALA-105 for solid tumours and initiated preclinical studies with armouring technology.

• Strengthened leadership with new board appointments and clinical advisors to support growth and development.

Financial highlights

• Revenue for FY26 was nil, down from $136,000 in FY25.

• Net loss after tax decreased 7.9% to $6,916,453 (FY25: $7,509,166).

• Net tangible assets per share fell to 1.17 cents (FY25: 1.69 cents).

• Cash reserves at year-end were $14,352,901, down from $20,877,185.

• No dividends declared or paid for the year.

Outlook and guidance

• Anticipates transformative year ahead with first-in-human clinical data from ALA-101.

• Plans to leverage clinical data for expansion into autoimmune diseases and additional solid tumour indications.

• Ongoing evaluation of strategic partnerships and technology acquisitions to broaden the platform.